Key result
Cardiovascular risk enrichment influences major cardiovascular events rates across tofacitinib rheumatoid arthritis clinical trials.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dougados et al. (2023) studied this question. Cardiovascular risk enrichment impacts the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Synapse has enriched 10 related papers. Consider them for comparative context: